New bladder cancer combo aims to boost immune attack
NCT ID NCT06963346
Summary
This early-stage study is testing whether adding a drug called romidepsin directly into the bladder can help another drug (durvalumab) work better against muscle-invasive bladder cancer. It is for patients who are not eligible for standard cisplatin chemotherapy. The main goal is to find a safe dose and see if the treatment helps shrink the tumor before surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.